Screener
Climb Bio, Inc. CLYM Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Climb Bio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Climb Bio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210357
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accounts payable | (1,409) | 72 |
| Accrued expenses and other current liabilities | (1,532) | 2,035 |
| Operating lease liabilities | (62) | (59) |
| Net cash used in operating activities | (14,379) | (15,434) |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (44,855) | (58,751) |
| Proceeds from maturities of marketable securities | 31,900 | 16,000 |
| Net cash used in investing activities | (12,955) | (42,751) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Climb Bio, Inc.'s operating cash flow?
- Climb Bio, Inc. (CLYM) reported operating cash flow of -$14.38M in Q1 2026.
- How has Climb Bio, Inc.'s operating cash flow changed year-over-year?
- Climb Bio, Inc.'s operating cash flow increased by 6.8% year-over-year, from -$15.43M to -$14.38M.
- What is the long-term trend for Climb Bio, Inc.'s operating cash flow?
- Over 3 years (2021 to 2025), Climb Bio, Inc.'s operating cash flow has grown at a 14.6% compound annual growth rate (CAGR), from -$36.07M to -$54.36M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Climb Bio, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude